Denali Therapeutics Inc. (DNLI) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "DNLI"
      ],
      "issuer_cik": "0001714899",
      "owner_cik": "0001797826",
      "accession_number": "0001797826-26-000006",
      "form_type": "4",
      "filing_date": "2026-09-04",
      "period_of_report": "2026-09-02",
      "issuer_name": "Denali Therapeutics Inc.",
      "issuer_trading_symbol": "DNLI",
      "owner_name": "Thornberry Nancy",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-02",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 615,
      "transaction_price_per_share": 23.74,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 19686,
      "transaction_value": 14600.099999999999,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026."
        },
        {
          "id": "F4",
          "description": "The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."
        },
        {
          "id": "F3",
          "description": "Includes 6,408 Unvested RSUs."
        }
      ]
    },
    {
      "tickers": [
        "DNLI"
      ],
      "issuer_cik": "0001714899",
      "owner_cik": "0001797826",
      "accession_number": "0001797826-26-000006",
      "form_type": "4",
      "filing_date": "2026-09-04",
      "period_of_report": "2026-09-02",
      "issuer_name": "Denali Therapeutics Inc.",
      "issuer_trading_symbol": "DNLI",
      "owner_name": "Thornberry Nancy",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-02",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 10824,
      "transaction_price_per_share": 22.85,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 20301,
      "transaction_value": 247328.40000000002,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026."
        },
        {
          "id": "F2",
          "description": "The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."
        },
        {
          "id": "F3",
          "description": "Includes 6,408 Unvested RSUs."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.